Analysts Issue Forecasts for KROS Q1 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Keros Therapeutics in a report released on Thursday, February 27th. William Blair analyst M. Phipps expects that the company will post earnings of ($0.61) per share for the quarter. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. William Blair also issued estimates for Keros Therapeutics’ Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.62) EPS and FY2028 earnings at ($2.14) EPS.

KROS has been the topic of several other reports. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. Wedbush cut Keros Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $47.00 to $15.00 in a report on Friday, January 17th. HC Wainwright dropped their price target on Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Piper Sandler reduced their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, January 17th. Finally, BTIG Research cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.33.

Keros Therapeutics Trading Up 0.2 %

Shares of NASDAQ KROS opened at $11.10 on Monday. The company’s 50-day moving average price is $12.40 and its 200 day moving average price is $39.25. Keros Therapeutics has a 52 week low of $9.77 and a 52 week high of $72.37. The stock has a market cap of $449.63 million, a price-to-earnings ratio of -2.13 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. AlphaQuest LLC boosted its position in shares of Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after acquiring an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC raised its stake in Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. KBC Group NV boosted its holdings in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Keros Therapeutics during the 4th quarter worth $90,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.